Bo Kruse is CFO & VP +1 at Y-mAbs Therapeutics, Inc. (YMAB). They have made 18 open-market trades across 1 company since 2020, most recently 2024-05-31.
CIK 0001752940
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 18 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| YMAB | 210,877 | $1.8M |
Shares reported on the most recent Form 4, priced at the 2024-05-31 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| YMAB | SELL | 2024-05-30 | 2024-05-31 | $12.05 | $1.4M | -0.8% | -2.4% | +15.7% |
| YMAB | SELL · 10b5-1 | 2022-02-22 | 2022-02-23 | $7.85 | $31K | +11.8% | +59.9% | +39.0% |
| YMAB | SELL · 10b5-1 | 2022-02-04 | 2022-02-07 | $7.97 | $32K | +5.7% | +24.1% | +9.6% |
| YMAB | SELL · 10b5-1 | 2022-01-24 | 2022-01-25 | $9.84 | $39K | -30.4% | -27.6% | +0.1% |
| YMAB | SELL | 2022-01-04 | 2022-01-05 | $17.12 | $68K | -26.7% | -49.0% | -9.0% |
| YMAB | SELL | 2021-12-22 | 2021-12-23 | $16.36 | $65K | -12.0% | -36.1% | -27.8% |
| YMAB | SELL | 2021-12-06 | 2021-12-07 | $16.35 | $131K | -4.9% | -12.2% | -51.1% |
| YMAB | SELL | 2021-11-22 | 2021-11-23 | $18.09 | $72K | -3.0% | +3.6% | -53.7% |
| YMAB | SELL | 2021-11-04 | 2021-11-05 | $27.54 | $110K | -14.6% | -25.8% | -64.5% |
| YMAB | SELL | 2021-10-22 | 2021-10-26 | $25.94 | $104K | -12.0% | -32.1% | -56.5% |
| YMAB | SELL | 2021-10-04 | 2021-10-05 | $28.78 | $115K | -2.8% | -13.6% | -36.5% |
| YMAB | SELL | 2021-09-22 | 2021-09-23 | $30.82 | $123K | -5.9% | -12.9% | -42.4% |
| YMAB | SELL | 2021-09-07 | 2021-09-08 | $32.03 | $128K | -1.6% | -12.7% | -45.0% |
| YMAB | SELL | 2021-08-23 | 2021-08-24 | $28.60 | $114K | +10.7% | +3.4% | -40.9% |
| YMAB | SELL | 2021-08-04 | 2021-08-05 | $33.72 | $135K | -26.5% | -18.1% | -29.0% |
| YMAB | SELL | 2021-07-22 | 2021-07-26 | $34.50 | $138K | +14.8% | -11.2% | -20.3% |
| YMAB | SELL | 2021-07-06 | 2021-07-07 | $34.15 | $137K | -2.3% | -8.2% | -12.2% |
| YMAB | SELL | 2021-06-22 | 2021-06-23 | $36.17 | $145K | -5.8% | +2.1% | -10.6% |
| YMAB | SELL | 2021-06-04 | 2021-06-07 | $33.48 | $134K | +7.3% | -9.1% | -9.0% |
| YMAB | SELL | 2021-05-24 | 2021-05-26 | $35.61 | $142K | -3.9% | -7.5% | -22.3% |
| YMAB | SELL | 2020-05-13 | 2020-05-15 | $36.66 | $7.3M | -6.1% | +12.0% | +4.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.